Conversely, the dopamine D2 receptor agonist bromocriptine, approved for use to treat diabetes because of its ability to reduce hyperglycemia in individuals with type 2 diabetes mellitus (Barnett et al., 1980), decreases adiposity in both humans (Meier et al., 1992) and other mammals (Cincotta et al., 1991, 1997). Here, DRD2 is linked to diabetes mellitus.